Evidence map›Paper›PMID 33469799›Full record

ArticleFamilial cancer2022

Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.

Paola Nix, Erin Mundt, Bradford Coffee, Elizabeth Goossen, Bryan M Warf, Krystal Brown, Karla Bowles, Benjamin Roa

Open access · hybridAbstract read
In one paragraph

Article in Familial cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Paola NixMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA. pnix@myriad.com.ORCID 0000-0002-9257-3724
Erin MundtMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Bradford CoffeeMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Elizabeth GoossenMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Bryan M WarfMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Krystal BrownMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Karla BowlesMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Benjamin RoaMyriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT, USA.
Myriad Genetics · USMyriad (Germany) · DEThird Wave Systems (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A substantial proportion of pathogenic variants associated with an increased risk of hereditary cancer are sequence variants affecting RNA splicing. The classification of these variants can be complex when both non-functional and functional transcripts are produced from the variant allele. We present four BRCA2 splice site variants with complex variant interpretations (BRCA2 c.68-3T>G, c.68-2A>G, c.425G>T, c.8331+2T>C). Evidence supporting a pathogenic classification is available for each variant, including in silico models, absence in population databases, and published functional data. However, comprehensive RNA analysis showed that some functional transcript may be produced by each variant. BRCA2 c.68-3T>G results in a partial splice defect. For BRCA2 c.68-2A>G and c.425G>T, aberrant splicing was shown to produce a potentially functional, in-frame transcript. BRCA2 c.8331+2T>C may utilize a functional GC donor in place of the wild-type GT donor. The severity of cancer history for carriers of these variants was also assessed using a history weighting algorithm and was not consistent with pathogenic controls (carriers of known pathogenic variants in BRCA2). Due to the conflicting evidence, our laboratory classifies these BRCA2 variants as variants of uncertain significance. This highlights the importance of evaluating new and existing evidence to ensure accurate variant classification and appropriate patient care.

Indexed as

BRCA2 ProteinBreast NeoplasmsBRCA1 ProteinFemaleGenes, BRCA2HumansMutationRNA, MessengerRNA Splice SitesRNA SplicingBRCA1 ProteinBRCA2 ProteinBRCA2 protein, humanRNA, MessengerRNA Splice SitesBRCA2Hereditary cancer syndromesPathogenicityRNA analysisSplice variants

Identifiers

PMID33469799
PMCPMC8799590
OpenAlexW3122156114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.